BIOHYBRID (Biohybrid templates for peripheral nerve regeneration) is a medium scale integrated project supported by the European Commission under the Seventh Framework Programm FP7 running from October 2011 until September 2015.
Successful conclusion of the
3rd International Symposium on Peripheral Nerve Regeneration
The BIOHYBRID Consortium successfully hosted the 3rd International Symposium on Peripheral Nerve Regeneration on September 24th and 25th, 2015 in Hannover.
More details will follow soon, in the meantime please visit www.ispnr.eu
New Publications from the BIOHYBRID Consortium
The Consortium has added two successful scientific papers at renowned publishing houses:
Shapira, Y., Tolmasov, M., Nissan, M., Reider, E., Koren, A., Biron, T., Bitan, Y., Geuna, S., Rochkind, S. Comparison of results between chitosan hollow tube and autologous nerve graft in reconstruction of peripheral nerve defect: An experimental study. Microsurgery, April 2015. DOI: 10.1002/micr.22418
Meyer, C.,Wrobel, S., Raimondo, S., Rochkind, S., Heimann, C., Shahar, A., Ziv-Polat, O., Geuna, S., Grothe, C., Haastert-Talini, K. Peripheral nerve regeneration through hydrogel enriched chitosan tubes containing engineered Schwann cells for drug delivery. Cell Transplantation, April 2015, in press
Website online! The European Society for the Study of Peripheral Nerve Repair and Regeneration- ESPNR was founded in May
You can now learn more about the aims and activities of the ESPNR by visiting www.espnr.eu.
The overall aim of the BIOHYBRID consortium is the preclinical development of an innovative artificial biohybrid nerve device for the regenerative treatment of traumatic injuries of peripheral nerves.
The consortium consists of three dynamic and reputable Small and Medium Enterprises (SMEs) as well as seven academic partners that are recognised leaders in the disciplines of neuroanatomy, neuronal regeneration, neurosurgery and innovative biomaterial research.
The results of the multidisciplinary research will feed into the establishment of artificial biohybrid devices as stand alone alternatives to accepted standard procedures and tools. Furthermore, standardised application guidelines and evaluation parameters will be set up to enable continuous progress and evaluation of the outcome of clinical application.